Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Redemption for the field of oncolytic virotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy

Kirn DH.
PMID: 21455205
Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45.

No abstract available.

Cite
Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther. 2011;19(4):627-8doi: 10.1038/mt.2011.45.
Kirn, D. H. (2011). Redemption for the field of oncolytic virotherapy. Molecular therapy : the journal of the American Society of Gene Therapy, 19(4), 627-8. https://doi.org/10.1038/mt.2011.45
Kirn, David H. "Redemption for the field of oncolytic virotherapy." Molecular therapy : the journal of the American Society of Gene Therapy vol. 19,4 (2011): 627-8. doi: https://doi.org/10.1038/mt.2011.45
Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45. PMID: 21455205; PMCID: PMC3070109.
Copy Download .nbib Format: NLM
Reovirus: viral therapy for cancer 'as nature intended'.

Clinical oncology (Royal College of Radiologists (Great Britain))

Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H.
PMID: 18583112
Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25.

Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief...

Cite
Comins C, Heinemann L, Harrington K, et al. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008;20(7):548-54doi: 10.1016/j.clon.2008.04.018.
Comins, C., Heinemann, L., Harrington, K., Melcher, A., De Bono, J., & Pandha, H. (2008). Reovirus: viral therapy for cancer 'as nature intended'. Clinical oncology (Royal College of Radiologists (Great Britain)), 20(7), 548-54. https://doi.org/10.1016/j.clon.2008.04.018
Comins, C, et al. "Reovirus: viral therapy for cancer 'as nature intended'." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 20,7 (2008): 548-54. doi: https://doi.org/10.1016/j.clon.2008.04.018
Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25. PMID: 18583112.
Copy Download .nbib Format: NLM
Personalized virotherapy in cancer.

Aging

Cafferata EG, Podhajcer OL.
PMID: 26022702
Aging (Albany NY). 2015 May;7(5):288-9. doi: 10.18632/aging.100750.

No abstract available.

Cite
Cafferata EG, Podhajcer OL. Personalized virotherapy in cancer. Aging (Albany NY). 2015;7(5):288-9doi: 10.18632/aging.100750.
Cafferata, E. G., & Podhajcer, O. L. (2015). Personalized virotherapy in cancer. Aging, 7(5), 288-9. https://doi.org/10.18632/aging.100750
Cafferata, Eduardo G, and Podhajcer, Osvaldo L. "Personalized virotherapy in cancer." Aging vol. 7,5 (2015): 288-9. doi: https://doi.org/10.18632/aging.100750
Cafferata EG, Podhajcer OL. Personalized virotherapy in cancer. Aging (Albany NY). 2015 May;7(5):288-9. doi: 10.18632/aging.100750. PMID: 26022702; PMCID: PMC4468308.
Copy Download .nbib Format: NLM
Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Cancer gene therapy

Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J.
PMID: 30177818
Cancer Gene Ther. 2019 Mar;26(3):59-73. doi: 10.1038/s41417-018-0042-1. Epub 2018 Sep 04.

The 11th International Oncolytic Virus Conference (IOVC) was held from April 9-12, 2018 in Oxford, UK. This is part of the high-profile academic-led series of meetings that was started back in 2002 by Steve Russell and John Bell, with...

Cite
Dyer A, Baugh R, Chia SL, et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 2018;26(3):59-73doi: 10.1038/s41417-018-0042-1.
Dyer, A., Baugh, R., Chia, S. L., Frost, S., Iris, Jacobus, E. J., Khalique, H., Pokrovska, T. D., Scott, E. M., Taverner, W. K., Seymour, L. W., & Lei, J. (2019). Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer gene therapy, 26(3), 59-73. https://doi.org/10.1038/s41417-018-0042-1
Dyer, Arthur, et al. "Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference." Cancer gene therapy vol. 26,3 (2019): 59-73. doi: https://doi.org/10.1038/s41417-018-0042-1
Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 2019 Mar;26(3):59-73. doi: 10.1038/s41417-018-0042-1. Epub 2018 Sep 04. PMID: 30177818.
Copy Download .nbib Format: NLM
Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Human gene therapy

Duffy MR, Fisher KD, Seymour LW.
PMID: 28793793
Hum Gene Ther. 2017 Nov;28(11):1033-1046. doi: 10.1089/hum.2017.112. Epub 2017 Aug 01.

Oncolytic viruses (OVs) are quickly moving toward the forefront of modern medicines. The reward for the decades of research invested into developing viral platforms that selectively replicate in and lyse tumor cells while sparking anticancer adaptive immunity is presenting...

Cite
Duffy MR, Fisher KD, Seymour LW. Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Hum Gene Ther. 2017;28(11):1033-1046doi: 10.1089/hum.2017.112.
Duffy, M. R., Fisher, K. D., & Seymour, L. W. (2017). Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Human gene therapy, 28(11), 1033-1046. https://doi.org/10.1089/hum.2017.112
Duffy, Margaret R, et al. "Making Oncolytic Virotherapy a Clinical Reality: The European Contribution." Human gene therapy vol. 28,11 (2017): 1033-1046. doi: https://doi.org/10.1089/hum.2017.112
Duffy MR, Fisher KD, Seymour LW. Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Hum Gene Ther. 2017 Nov;28(11):1033-1046. doi: 10.1089/hum.2017.112. Epub 2017 Aug 01. PMID: 28793793.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries